resources

Aurobindo Pharma Ltd.

NSE: AUROPHARMA

BSE: 524804

Sector: Healthcare

Industry Group: Pharmaceuticals & Biotechnology

Industry: Pharmaceuticals

1,557.40-25.6 (-1.62%)

8 Jul, 12:00 AM

Overview Analysis Statements Technicals Forecast Peers Resources

News

Annual Reports and Financial Documents

Aurobindo Pharma Ltd. annual reports, quarterly results, earnings call transcripts and investor presentations. All official filings in one place.

	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026
Annual Reports	FY 2013	FY 2014	FY 2015	FY 2016	FY 2017	FY 2018	FY 2019	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	—
Quarterly Results	—	—	—	—	—	Dec	Mar Jun Sept Dec	Mar Jun Sept Dec	Mar Jun Sept Dec	Mar Sept Dec	Mar Jun Sept Dec	Mar Jun Sept Dec	Dec	Mar
Conference Calls	—	—	—	—	—	—	—	—	25Feb 11Jun 25Aug 19Nov	17Feb 6Jun 19Aug 18Nov	17Feb 1Jun 18Aug 15Nov	16Feb 31May 16Aug 18Nov	13Feb 2Jun 8Aug 11Nov	16Feb 27May
Presentations	—	—	—	—	—	—	—	—	10Feb 31May 12Aug 8Nov	9Feb 30May 11Aug 7Sept 12Nov	9Feb 27May 12Aug 9Nov	10Feb 13Mar 25May 10Aug 9Nov	6Feb 26May 4Aug 5Nov	9Feb 10Feb 21May

Corporate Announcements and Regulatory Filings

Aurobindo Pharma Ltd. BSE/NSE disclosures, board meeting outcomes, insider trading notifications, acquisitions and other regulatory filings.

Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 20182 Jul 2026
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Submission of certificate under regulation 74 (5) of SEBI (Depositories and Participants) Regulations, 2018 for the Quarter ended June 30, 2026.
General2 Jul 2026
Completion Of Transfer Of Company'S Domestic Branded Generic Pharmaceutical Formulations Products Business To Auropharm Limited, A Wholly Owned Subsidiary Of The Company
Intimation of completion of transfer of Company''s domestic branded generic pharmaceutical formulations products business to Auropharm Limited, a wholly owned subsidiary of the Company.
Acquisition30 Jun 2026
Announcement under Regulation 30 (LODR)-Updates on Acquisition
Intimation of completion of acquisition of Lannet by Aurobindo Pharma USA Inc, a wholly owned subsidiary of the Company.
General27 Jun 2026
Completion Of US FDA Inspection At Auroactive Pharma Private Limited, A Wholly Owned Subsidiary Of The Company.
Intimation of completion of US FDA inspection at Auroactive Pharma Private Limited, a wholly owned subsidiary of the Company.
Acquisition25 Jun 2026
Announcement under Regulation 30 (LODR)-Updates on Acquisition
Intimation of completion of acquisition.
Closure of Trading Window25 Jun 2026
Closure of Trading Window
Intimation of closure of Trading Window
Press Release / Media Release22 Jun 2026
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Submission of Press Release that is being issued by the Company.
General19 Jun 2026
Completion Of US FDA Pre-Approval Inspection (PAI) At Eugia Steriles Private Limited, A 100% Stepdown Subsidiary Of The Company
Intimation of completion of US FDA Pre-Approval Inspection (PAI) at Eugia Steriles Private Limited, a 100% stepdown subsidiary of the Company.
General19 Jun 2026
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.
Intimation of receipt of necessary approvals from US Federal Trade Commission (FTC) for the acquisition of Lannett business.
General12 Jun 2026
Classification Of US FDA Inspection At Unit-III Of Eugia Pharma Specialities Limited, Pashamylaram (Our Wholly Owned Subsidiary) As OAI
Intimation of US FDA Inspection at Unit-III of Eugia Pharma Specialities Limited, a wholly owned subsidiary of the Company as OAI.
Newspaper Publication11 Jun 2026
Announcement under Regulation 30 (LODR)-Newspaper Publication
Submission of notice published in the newspapers.
Analyst / Investor Meet9 Jun 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Participation in Investor meeting to be held on June 12, 2026
Analyst / Investor Meet5 Jun 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Participation in Investor meeting to be held on June 10, 2026
Press Release / Media Release4 Jun 2026
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Submission of press release that is being issued in connection with receipt of final US FDA approval for Tafacitinib tablets 5 mg and 10 mg.
Press Release / Media Release3 Jun 2026
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Submission of press release that is being issued by the Company in connection with inauguration of Theranym- Pioneering India''s Large Scale Biologics Contract Manufacturing Facility of ....
Analyst / Investor Meet3 Jun 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of investor meeting to be held on June 8, 2026 at Mumbai
Analyst / Investor Meet27 May 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Investor meet at Investec US Pharma and Healthcare Bus Tour 7.0 in New Jersey, USA.
Analyst / Investor Meet27 May 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Participation in Investor meet at BofA 2026 India Conference at Mumbai
Analyst / Investor Meet25 May 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of investor meet to be held on Mary 29, 2026.
General24 May 2026
Classification Of Unit-I Of Eugia Pharma Specialities Limited, Shameerpet (Our Wholly Owned Subsidiary) As OAI
Intimation of classification of Unit-1 of Eugia Pharma Specialities Limited, a wholly owned subsidiary of the Company.

Frequently Asked Questions

Where can I download the annual report of Aurobindo Pharma Ltd.?

Annual reports of Aurobindo Pharma Ltd. are available for download in the Annual Reports and Financial Documents section of the Resources tab, organised by financial year.

Where can I find the quarterly results of Aurobindo Pharma Ltd.?

Quarterly earnings results and presentations of Aurobindo Pharma Ltd. are available in the Annual Reports and Financial Documents section of the Resources tab. Detailed financials are also in the Statements tab.

Does Aurobindo Pharma Ltd. publish earnings call transcripts?

Earnings call transcripts of Aurobindo Pharma Ltd., where available, are listed in the Annual Reports and Financial Documents section of the Resources tab.

Where can I find investor presentations of Aurobindo Pharma Ltd.?

Investor presentations and annual day presentations of Aurobindo Pharma Ltd. are listed in the Resources tab under Annual Reports and Financial Documents.

What are the recent corporate announcements of Aurobindo Pharma Ltd.?

Corporate announcements and regulatory filings of Aurobindo Pharma Ltd. as submitted to BSE and NSE are available in the Corporate Announcements and Regulatory Filings section of the Resources tab.

How do I access the regulatory filings of Aurobindo Pharma Ltd.?

Regulatory filings including board meeting outcomes, insider trading disclosures and other exchange notifications of Aurobindo Pharma Ltd. are in the Corporate Announcements and Regulatory Filings section of the Resources tab.

What is the ISIN of Aurobindo Pharma Ltd.?

The ISIN (International Securities Identification Number) of Aurobindo Pharma Ltd. is INE406A01037. This is the unique identifier used across exchanges and depositories.

On which stock exchange is Aurobindo Pharma Ltd. listed?

Aurobindo Pharma Ltd. is listed on NSE and BSE. The NSE symbol is AUROPHARMA and the BSE code is -.

Where can I find the shareholding pattern of Aurobindo Pharma Ltd.?

The quarterly shareholding pattern of Aurobindo Pharma Ltd. showing promoter, FII, DII, mutual fund and public holdings is available in the Shareholding Pattern section on the Overview tab.

How current is the data for Aurobindo Pharma Ltd. on Sharpely?

Share price data for Aurobindo Pharma Ltd. is updated as of 8 Jul 2026. Financial statements, shareholding and other fundamental data are updated after each quarterly disclosure.